FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201991314> ?p ?o ?g. }

• W3201991314 abstract "Patients with locally advanced esophageal squamous cell carcinoma (ESCC) show poor survival after concurrent chemoradiotherapy. This study investigated the safety and feasibility of combining concurrent chemoradiotherapy with the anti-PD-1 antibody camrelizumab as first-line treatment for these patients. In this phase 1b study (ClinicalTrials.gov NCT03671265), patients received concurrent chemotherapy (cisplatin [25 mg/m2] plus docetaxel [25 mg/m2] for 4 weeks) and radiotherapy (2.0 Gy/fraction, total 60 Gy) with camrelizumab (200 mg every 2 weeks for 32 weeks). Primary endpoints were safety and tolerability, and health-related quality of life. Secondary endpoints were radiological and pathological response rates, overall survival (OS), and progression-free survival (PFS). Candidate biomarkers in tumor and peripheral blood were monitored at baseline and after 40 Gy radiation. Twenty patients were enrolled. The most common treatment-related grade 3 adverse events included radiation esophagitis (20%) and esophageal fistula (10%). Serious treatment-related adverse events occurred in eight (40%) patients. No treatment-related deaths were reported. Health-related quality of life did not deteriorate. Thirteen (65%) patients had an objective response after 40 Gy radiation. At a median follow-up of 23.7 months (95% CI 21.9-24.5), OS and PFS time ranged from 8.2-28.5 and 4.0-28.5 months, respectively. The 12-month and 24-month OS rate was 85.0% and 69.6%; PFS rate was 80.0% and 65.0%. Tumor PD-L1 expression and CD11c+ dendritic cells and peripheral-blood IL-27, IL-15, Eotaxin-3, and IL-22 were associated with OS. First-line concurrent chemoradiotherapy plus camrelizumab had a manageable safety profile and promising antitumour efficacy for ESCC, and deserves further study." @default.
• W3201991314 created "2021-10-11" @default.
• W3201991314 creator A5004476606 @default.
• W3201991314 creator A5005514451 @default.
• W3201991314 creator A5008204710 @default.
• W3201991314 creator A5012342469 @default.
• W3201991314 creator A5021453588 @default.
• W3201991314 creator A5024902063 @default.
• W3201991314 creator A5025277732 @default.
• W3201991314 creator A5028097829 @default.
• W3201991314 creator A5033510051 @default.
• W3201991314 creator A5034291484 @default.
• W3201991314 creator A5042241049 @default.
• W3201991314 creator A5053769864 @default.
• W3201991314 creator A5060589194 @default.
• W3201991314 creator A5064729480 @default.
• W3201991314 creator A5072571039 @default.
• W3201991314 creator A5076930880 @default.
• W3201991314 creator A5086373223 @default.
• W3201991314 creator A5090340361 @default.
• W3201991314 date "2021-01-01" @default.
• W3201991314 modified "2023-10-14" @default.
• W3201991314 title "Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study" @default.
• W3201991314 cites W2120072658 @default.
• W3201991314 cites W2144263975 @default.
• W3201991314 cites W2144846148 @default.
• W3201991314 cites W2160981405 @default.
• W3201991314 cites W2166101858 @default.
• W3201991314 cites W2272984102 @default.
• W3201991314 cites W2276228008 @default.
• W3201991314 cites W2282962877 @default.
• W3201991314 cites W2394989507 @default.
• W3201991314 cites W2399697387 @default.
• W3201991314 cites W2401439946 @default.
• W3201991314 cites W2617691667 @default.
• W3201991314 cites W2724177236 @default.
• W3201991314 cites W2739995497 @default.
• W3201991314 cites W2743787112 @default.
• W3201991314 cites W2765434473 @default.
• W3201991314 cites W2767287110 @default.
• W3201991314 cites W2769696597 @default.
• W3201991314 cites W2770898858 @default.
• W3201991314 cites W2789258259 @default.
• W3201991314 cites W2795888701 @default.
• W3201991314 cites W2799845177 @default.
• W3201991314 cites W2804526851 @default.
• W3201991314 cites W2807864393 @default.
• W3201991314 cites W2889646458 @default.
• W3201991314 cites W2890100090 @default.
• W3201991314 cites W2893399598 @default.
• W3201991314 cites W2897612290 @default.
• W3201991314 cites W2905105365 @default.
• W3201991314 cites W2908581980 @default.
• W3201991314 cites W2914792906 @default.
• W3201991314 cites W2924582533 @default.
• W3201991314 cites W2943432615 @default.
• W3201991314 cites W2949012929 @default.
• W3201991314 cites W2950419847 @default.
• W3201991314 cites W2963970279 @default.
• W3201991314 cites W2976652879 @default.
• W3201991314 cites W2981650328 @default.
• W3201991314 cites W3005292744 @default.
• W3201991314 cites W3008514541 @default.
• W3201991314 cites W3011940221 @default.
• W3201991314 cites W3016064310 @default.
• W3201991314 cites W3025003676 @default.
• W3201991314 cites W3037386173 @default.
• W3201991314 cites W3081199965 @default.
• W3201991314 cites W3092384992 @default.
• W3201991314 cites W3095874142 @default.
• W3201991314 cites W3111745735 @default.
• W3201991314 cites W3121004177 @default.
• W3201991314 cites W3134507388 @default.
• W3201991314 cites W3156426224 @default.
• W3201991314 cites W3195935456 @default.
• W3201991314 cites W818981131 @default.
• W3201991314 doi "https://doi.org/10.1080/2162402x.2021.1971418" @default.
• W3201991314 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8489938" @default.
• W3201991314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34616588" @default.
• W3201991314 hasPublicationYear "2021" @default.
• W3201991314 type Work @default.
• W3201991314 sameAs 3201991314 @default.
• W3201991314 citedByCount "30" @default.
• W3201991314 countsByYear W32019913142022 @default.
• W3201991314 countsByYear W32019913142023 @default.
• W3201991314 crossrefType "journal-article" @default.
• W3201991314 hasAuthorship W3201991314A5004476606 @default.
• W3201991314 hasAuthorship W3201991314A5005514451 @default.
• W3201991314 hasAuthorship W3201991314A5008204710 @default.
• W3201991314 hasAuthorship W3201991314A5012342469 @default.
• W3201991314 hasAuthorship W3201991314A5021453588 @default.
• W3201991314 hasAuthorship W3201991314A5024902063 @default.
• W3201991314 hasAuthorship W3201991314A5025277732 @default.
• W3201991314 hasAuthorship W3201991314A5028097829 @default.
• W3201991314 hasAuthorship W3201991314A5033510051 @default.
• W3201991314 hasAuthorship W3201991314A5034291484 @default.
• W3201991314 hasAuthorship W3201991314A5042241049 @default.
• W3201991314 hasAuthorship W3201991314A5053769864 @default.
• W3201991314 hasAuthorship W3201991314A5060589194 @default.
• W3201991314 hasAuthorship W3201991314A5064729480 @default.

• next